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PROPORTIONATE AND ADAPTIVE GOVERNANCE OF INNOVATIVE TECHNOLOGY (PAGIT) 
EXECUTIVE SUMMARY 
Joyce Tait, Geoff Banda and Andrew Watkins 
1. Introduction 
The UK Government has ambitious plans to provide financial, organisational and structural 
support to the UK’s most innovative industry sectors. However, these investments will fail to 
deliver the expected benefits unless they are accompanied by targeted initiatives to make 
regulatory systems more proportionate and adaptive to the needs of innovative 
technologies. The framework developed for the PAGIT project will support improved, more 
evidence-based policy and regulatory decision making that takes account of the needs of 
innovative technologies and at the same time continues to ensure safety, quality and 
efficacy of the final products or processes. This approach has the potential also to 
contribute to the UK Government’s desire to lead internationally in developing a regulatory 
test-bed for innovative technologies. 
How we choose to regulate an innovative technology will define the future shape of the 
industry sectors that form around it, including the extent to which small and medium sized 
companies are able to thrive and grow independently of incumbent multinationals. Past 
regulatory choices, particularly for the most innovative technology areas have sometimes 
been idiosyncratic, reflecting a range of pressures from industry, policy makers, regulators 
and societal lobby groups. The end result has been that several regulatory systems have 
become complex, rigid, time consuming and, for smaller companies, prohibitively costly. In 
such circumstances, the innovation landscape is dominated by the business models of large 
multinational companies, with their preference for incremental rather than disruptive 
innovation. In such areas it is very difficult for a small or medium sized company to gain an 
independent competitive advantage based on a disruptive innovation and this loss of 
innovation potential will have a significant impact on the UK’s national and regional 
economies. 
The PAGIT Framework incorporates three principles to guide decision making - the EU 
innovation principle (“… to improve the quality and application of EU legislation and … to 
stimulate confidence, investment and innovation”) supported by the regulatory principles 
of proportionality and adaptation. It brings together the main actors in innovation 
ecosystems: scientists/innovators; policy makers/regulators; and citizens/stakeholders. 
The key to delivering these principles lies in considering the extent to which an innovative 
technology will be disruptive or incremental in its impact on company business models and 
sectoral value chains, illustrated by two case studies: (i) Active Implantable Medical Devices 
(an example of incremental innovation) and (ii) Synthetic Biology and Gene Editing (an 
example of disruptive innovation). Abiding by these principles will also require the main 
actors in innovation systems to comply with the proposed Responsibility Standard, with 
two component standards on Responsible Innovation and Responsible Engagement.  
This project could also contribute to advising the UK Government on meeting the Brexit-
related challenge to reconsider our regulatory systems as their administration is transferred 
from the current EU authorities to UK bodies.  
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2. A staged approach 
The PAGIT Framework (Figure 1) guides decision making for innovative technologies 
according to the Technology Readiness Level (TRL) reached by the innovation and the extent 
to which it is expected to be incremental or disruptive in its impact on the business models 
of incumbent companies. This relates the Framework to the innovation principle and guides 
further decision making on the basis of the principles of adaptation and proportionality.  
 For incremental innovation there will be a clear, uncontested choice of regulatory 
system, with post-regulatory standards and guidelines already in place. Where they are 
not well-matched to the properties of an innovation and are likely to constrain its future 
development, their adaptation can be a powerful enabler of innovation. For example, 
the US Food and Drug Administration changed the guidelines for the conduct of clinical 
trials for new antimicrobial drugs and brought down the cost of their development by 
~50%.  
 Disruptive innovation will be a much rarer occurrence than incremental innovation and 
it is also much more challenging for decision makers. There will be no clear choice of 
regulatory system for the new technology, or alternatively this choice may be contested.  
 
Figure 1. PAGIT Framework 
 
 
Building on this Framework, Figure 2 describes the decision processes for disruptive and 
incremental innovation. Disruptive innovation will require the full, staged decision making 
process, starting from TRLs 1 – 3, and for the much more common incremental innovation 
the process can begin at TRLs 6 – 7.  
(i) TRL 1-3 (Pre-Regulatory Standards). Focus on aspirational or consensus standards to 
support understanding of the properties of the innovation, including its potential risks 
and benefits and how they could best be governed. 
(ii) TRL 4-5 (Pre-Regulatory Guidelines). From these initial standards, develop more formal 
guidelines that could then, if necessary, form the basis of a future regulatory system. At 
this point decision makers should also be open to a conclusion that the proposed pre-
regulatory guidelines are sufficient to ensure safety, quality and efficacy of the 




(iii) TRL 6-7 (Regulations). Either decide which existing regulatory system is most 
appropriate to the properties of the innovative technology or, for the most radically 
disruptive technologies, consider devising a new regulatory approach. Legally binding 
regulations should be couched in general terms relating to their desired outcome and be 
backed up by post-regulatory standards and guidelines.  
(iv) TRL 8-9 (Post-Regulatory Standards and Guidelines). Devise standards and guidelines to 
support compliance with the regulatory system by those involved in developing the new 
technology.  
Figure 2. Using the PAGIT Framework for incremental or disruptive innovation 
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companies, citizens and stakeholders on a more equitable basis than currently prevails. This 
will contribute to achieving adaptation and proportionality in future regulatory systems.  
3. Outcomes from case study interviews and workshops  
Project participants generally supported the PAGIT Framework approach to regulation and 
governance of innovative technologies. Currently regulator/innovator interactions are often 
in the form of advice from regulators on how to adapt a non-routine innovation to the 
needs of the regulatory system excluding, as proposed here, also considering how to adapt 
the regulatory system to the needs of the innovation. The PAGIT Framework could make a 
difference by encouraging regulators and standards bodies to be more open to: (i) 
adaptation of post-regulatory standards and guidelines to meet the needs of incrementally 
innovative technologies, and (ii) development of pre-regulatory standards and guidelines as 
a prelude to making a decision on the appropriate regulatory system to be applied to a 
disruptive innovation. The role of the regulator would not change in either case from that of 
a legally-backed authority with jurisdiction over a specific area of human activity and there 
should be no diminution in safety, quality and efficacy requirements of innovative 
developments. 
The PAGIT Framework supports understanding of the complexities involved in categorising 
innovation as disruptive or incremental and in applying that understanding to real-world 
regulatory examples. This is an early step on the road to making regulatory systems more 
adaptive and proportionate to the needs of innovative technologies, complementing other 
EU and OECD initiatives. It demonstrates how one could deliver a governance approach that 
matches the innovation opportunities arising from 21st century science.  
Active implantable medical devices were chosen as an example of incremental innovation 
but some of the most innovative developments are likely to require very significant 
adaptation of post-regulatory standards and guidelines. They will be subject in future to the 
requirements of the EU Medical Devices Regulation (2017), with post-regulatory standards 
and guidelines currently in development. This creates an opportunity for regulators and 
standards bodies to engage with innovators to consider how, if necessary, to adapt the post-
regulatory standards and guidelines to meet the needs of innovative developments that 
challenge the processes in place for existing technologies. 
The case study on synthetic biology and gene editing was initially classed as an example of 
disruptive innovation but during the project some developments were redefined as 
incremental. Examples of incremental innovation in this area would be development by an 
agro-biotechnology company of improved versions of GM crops or where a company with 
expertise in fermentation technology uses micro-organisms to manufacture biofuels or new 
intermediates for chemical manufacturing companies.  
Disruptive innovation opportunities from synthetic biology and gene editing include opening 
up niche markets for crop-related developments that are too small to be of interest to the 
multinational agro-biotechnology industry sector, but that could grow to become a 
significant parallel sector in the bioeconomy. For these disruptive opportunities there are 
several potential regulatory precedents in a range of countries, none without some 
disagreement about its proportionality. It would be appropriate to consider adopting the full 
framework approach for such cases, beginning with pre-regulatory standards and guidelines 
at TRLs 1 – 5. For these applications project participants proposed that regulators should be 
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open to concluding at TRL 5 that there is no need for legally based oversight beyond pre-
regulatory guidelines. 
There was also support for the development of a Responsibility Standard with two elements 
(Responsible Innovation and Responsible Engagement) (Figure 3).  
(i) The overall Responsible Innovation Standard would include a Corporate Responsible 
Innovation Standard to guide a company’s general behaviour, implemented through its 
standard operating procedures. For most incremental innovation, no further action 
would be required of companies. Where a disruptive innovation is involved or where 
there is significant societal interest in it, companies should also monitor innovation-
specific elements of the development, including societal and environmental risks and 
benefits, through a Consolidated Responsible Innovation Framework (CRIF) from TRLs 4-
9. 
(ii) The Responsible Engagement Standard and associated guidelines would require all 
stakeholders, citizens and advocacy groups as well as industry, to engage responsibly. 
This is more equitable than the current approach which focuses almost entirely on 
responsible behaviour by companies.  
Figure 3. Using the PAGIT Responsibility Standard 
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4. Conclusions and recommendations 
The report’s conclusions are relevant to a broad range of innovative technologies and 
sectors where the UK sees itself as leading in the field. These include autonomous and low-
emission vehicles, FinTech, robotics, aerospace, battery technologies, chemicals and 
industrial biotechnology and life sciences (pharmaceuticals, cell therapies, gene editing, 
synthetic biology, stratified medicine, agricultural and food technologies). The BSI could take 
a major role in implementing this approach, leading to more proactive involvement of 
standards in regulatory systems, particularly for the most innovative technologies. It could 
also have a major role in supporting the adaptation of UK regulatory systems to address the 
implications of the Brexit decision without damaging future international trading prospects. 
Most elements of the Framework are not in themselves novel and many are elements of at 
least some current regulatory systems. The novelty of the approach lies in its ability to 
manage the systemic interactions across different industry sectors at different stages in 
development of an innovative technology, with different elements of regulatory systems, 
and different stakeholder constituencies. If the PAGIT Framework could succeed in 
supporting more effective management of these interactions, even to a modest degree, we 
could see a dramatic improvement in the value for money generated from public and 
private investment in scientific research. 
The following further developments are proposed: 
(i) Application of the PAGIT Framework to imminent decisions in the UK on future 
regulation of SB and GE, building on the case study conducted here, potentially involving 
BSI; 
(ii) Immediate moves towards development of an overall Responsibility Standard, including 
Responsible Innovation and Responsible Engagement Standards, again potentially 
involving BSI; 
(iii) Continued involvement of BSI in the development of post-regulatory standards and 
guidelines for active implantable medical devices, being alert to any opportunities that 
arise over the next three years to adapt these instruments to the needs of the most 
innovative developments; 
(iv) Development of further case studies on potentially disruptive technologies to enable 
wider uptake of the PAGIT approach.  
(v) Development of a detailed analysis of the opportunities to use the PAGIT approach to 
optimise the UK’s future regulatory systems for innovative technologies in the context of 
the Brexit negotiations. 
 
